DX5057

DX5057 is an orally bioavailable small molecule inhibitor developed by Altay Therapeutics for the treatment of facioscapulohumeral muscular dystrophy (FSHD). FSHD is a rare genetic muscle disorder caused by the aberrant expression of the DUX4 transcription factor, which leads to muscle cell death and progressive muscle weakness. DX5057 is designed to bind directly to DUX4, inhibiting its transcriptional activity and rescuing muscle cells from DUX4-induced toxicity. As a first-in-class therapeutic, it has demonstrated preclinical efficacy comparable to injectable gene-targeting therapies. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to DX5057, recognizing its potential as the first oral small molecule DUX4 inhibitor in development for this indication.